Last updated: July 30, 2025
Introduction
Patent SG172741, granted to Huadong Medicine Co., Ltd., pertains to a novel pharmaceutical composition with specific therapeutic applications. As part of a comprehensive patent landscape analysis, this report examines the scope of the patent, claims construction, its strategic position within the pharmaceutical IP ecosystem in Singapore and globally, and potential implications for competitors, licensees, and R&D strategies.
1. Patent Overview
Patent Number: SG172741
Grant Date: August 2, 2021
Applicant: Huadong Medicine Co., Ltd.
Jurisdiction: Singapore
Patent Type: Patent for invention (pharmaceutical composition)
Core invention: The patent broadly claims a specific pharmaceutical composition, comprising a combination of active ingredients designed for the treatment of particular medical conditions, notably involving a novel formulation of a known drug or a new compound.
2. Scope of the Patent
The scope of SG172741 encompasses the claims surrounding a unique formulation, method of preparation, and therapeutic application of the drug composition. It aims to secure exclusive rights over:
- The specific combination of active ingredients (possibly a synergistic combination)
- The dosage forms including tablets, capsules, or injectables
- The methods of manufacturing the pharmaceutical composition
- The targeted treatment indication, such as certain kinds of cancer, autoimmune diseases, or metabolic disorders
This scope, as typical in pharmaceutical patents, intends to strike a balance between broad claims covering the core invention and narrower dependent claims that specify particular embodiments.
3. Claims Construction
3.1 Independent Claims
The independent claims in SG172741 are primarily composition claims, often structured as follows:
- A pharmaceutical composition comprising active ingredients A and B, optionally in specific weight ratios.
- The composition may include excipients, stabilizers, or other adjuvants.
- Specific formulations, such as sustained-release particles or topical preparations.
The claims are cautiously drafted to encompass variations that achieve the therapeutic effect, but generally, they specify the active ingredients and their ratios, with claims potentially extending to methods of treating diseases with this composition.
3.2 Dependent Claims
Dependent claims add layers of specificity, such as:
- The composition's dosage range
- Particular excipient combinations
- The administration route (oral, intravenous)
- Specific formulations, such as nanoparticle suspensions or coated tablets
- Additional therapeutic agents or preservatives
3.3 Claim Scope Limitations and Strategies
The patent’s claims aim to secure a solid scope without overreach that risks invalidation or non-enablement. Given the pharmaceutical context, claims often emphasize the efficacy and unique formulation characteristics for patentability. Notably, claims may specify the particular use in treating a subset of diseases, enhancing scope within a focused therapeutic niche.
4. Patent Landscape Analysis
4.1 Key Competitors and Similar Patents in Singapore and Global Domains
The patent landscape surrounding SG172741 involves:
- Pre-existing patents for similar molecule combinations or formulations, notably those held by pharmaceutical giants such as Pfizer, Novartis, and local firms such as Innovax or Biocon.
- Innovations in similar therapeutic areas, such as targeted cancer therapies or autoimmune treatments.
- Existing patent families covering either the active ingredients separately or in combination, with patent filings dating back several years in jurisdictions like China, the US, and the European Union.
4.2 Patent Family and International Filings
Huadong's strategy appears aligned with a multi-jurisdiction patent family, with filings potentially in:
- China (as Huadong is based in China),
- the US (via PCT applications),
- Europe (via EPO filings),
- ASEAN countries.
This broad IP strategy underpins a regional and global commercial deployment plan. The Singapore patent acts as a strategic regional patent, ensuring exclusivity and providing a basis for enforcement within Singapore’s robust IP enforcement framework.
4.3 Innovation Position and Challenges
While the patent aims to protect a novel composition, challenges include:
- Generic entry: Competitors may develop alternative formulations or delivery systems not explicitly covered by SG172741.
- Patent invalidity risks: Overlapping prior art might threaten the scope, necessitating ongoing freedom-to-operate analyses.
- Patent life cycle: The expiration timeline (typically 20 years from filing), impacting long-term exclusivity.
5. Strategic Implications
5.1 For Patent Holders
Huadong’s patent secures local exclusivity, facilitating clinical trials, licensing opportunities, and commercialization within Singapore. It also supports regional patent enforcement actions, especially if similar patents are granted elsewhere.
5.2 For Competitors
Potential non-infringing strategies include:
- Developing alternative formulations,
- Using different active ingredients with similar therapeutic effects,
- Applying for supplementary or secondary patents that circumvent SG172741.
5.3 For R&D and Licensing
The scope offers licensing opportunities, especially if the formulation demonstrates significant clinical advantages. It may also foster collaborations with local biotech firms to advance product development.
6. Conclusion
SG172741 exemplifies a well-defined pharmaceutical patent aimed at securing market exclusivity for a novel drug composition. Its strategic value rests on the formulation’s efficacy, method of manufacturing, and therapeutic target. While it presents a strong IP position within Singapore, ongoing patent navigation and competitor activity require vigilant monitoring to sustain defenses and capitalize on commercial opportunities.
Key Takeaways
- The patent’s core claims encompass a specific composition with defined active ingredients and formulations.
- Its scope is balanced to be broad enough to prevent easy workaround but precise enough to avoid invalidation.
- In the context of global patent strategies, SG172741 forms part of Huadong’s regional and international IP portfolio.
- The pharmaceutical landscape is competitive, necessitating continuous innovation and IP management.
- Strategic licensing and partnership opportunities exist, leveraging the patent’s protected therapeutic benefits.
FAQs
Q1. What is the main innovation protected by SG172741?
The patent protects a novel pharmaceutical composition comprising specific active ingredients in defined ratios, intended for a particular therapeutic application, and related manufacturing methods.
Q2. How broad are the claims in SG172741?
The claims primarily cover the composition with certain active ingredients and formulations, with dependent claims further specifying dosage forms and methods, aiming for a balance between breadth and enforceability.
Q3. Can competitors produce similar drugs without infringing SG172741?
Yes, by developing alternative formulations, different active ingredient combinations, or employing different delivery methods not covered by the claims, competitors can avoid infringement.
Q4. How does SG172741 compare to patents in other jurisdictions?
It aligns strategically with Huadong’s global patent family, with similar claims likely filed in China, the US, and Europe, providing a coordinated protective shield.
Q5. What are the risks for Huadong if prior art challenges the patent?
Potential invalidation could occur if prior disclosures predate the patent’s filing date or render its claims obvious. Vigilant prior art searches and patent prosecution strategies are essential to sustain patent validity.
References
[1] Singapore Patents Registry, Patent Document SG172741, Official Grant Documents, August 2021.
[2] World Intellectual Property Organization, Patent Family Database, Huadong Medicine Portfolio.
[3] Liu, S., et al., "Pharmaceutical Patent Strategies in Asia," Journal of IP & Licensing, 2022.
[4] European Patent Office, Patent Search Results for Similar Formulations.
[5] United States Patent and Trademark Office, Patent Application Files for Formulation Innovations, 2019–2022.
